市場調査レポート

新興の医薬品市場:2012年

Emerging Pharmaceutical Markets 2012

発行 SELECTBIO, Ltd. 商品コード 206589
出版日 ページ情報 英文 222 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
新興の医薬品市場:2012年 Emerging Pharmaceutical Markets 2012
出版日: 2011年06月30日 ページ情報: 英文 222 Pages
概要

新興経済圏における製薬市場の着実な成長は、世界の製薬市場全体の成長率を上回っています。新興市場の成長は、国の経済成長、1人あたりの所得の拡大、急速な都市化による生活習慣病の発症率の増加、低コストなどの要因によってもたらされています。世界の医薬品市場は、主にこういった新興国の好調な業績から、2012年末までに1兆200億米ドルの規模に達すると予測されています。

当レポートでは、新興国における製薬市場の動向について調査分析し、各市場の人口プロファイル、マクロ経済指標、疾患プロファイル、知的財産に関連する動向、市場機会、研究協力・提携、その他市場影響因子の分析などをまとめ、概略下記の構成でお届けいたします。

調査内容

  • 各市場の人口構成・社会経済的環境
  • 主要治療区分
  • ジェネリック薬への世界的移行の動向との比較
  • コラボレーション・パートナーシップ
  • ジェネリック薬の市場機会
  • 規制の枠組み・地域の法規制
  • 各市場の主要な調剤
  • 知的財産に関する法規制:概要
  • R&D
  • 各市場における主要企業

調査対象国・地域

  • インド
  • 中国
  • ロシア
  • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • ベネズエラ
    • コロンビア
    • ペルー
    • アルゼンチン
    • チリ
  • 東欧
    • ポーランド
    • チェコ共和国
    • ルーマニア
    • スロベニア
  • 中近東
    • エジプト
    • トルコ
    • サウジアラビア
    • イスラエル
    • ヨルダン
    • UAE
    • レバノン
    • クウェート
目次

The robust growth in the pharmaceutical markets of emerging world economies has outpaced the overall growth of the global pharmaceutical market. The emerging markets are being driven by rapidly growing economies of these countries, increasing per capita income, increasing prevalence of lifestyle diseases due to rapid urbanization, and low-cost factors. Mainly due to strong performance in the emerging pharmaceutical markets, the global pharmaceutical market is expected to reach US$ 1,020 Billion by the end of 2012. This research study provides extensive and coherent information about pharmaceutical markets in emerging countries. It also gives a detailed statistical and analytical review on the demographics, macroeconomic indicators, disease profile, key drivers and restraints of the emerging pharmaceutical markets.

The report covers all the key aspects of the various emerging pharmaceutical markets and has broadly outlined the factors that are affecting the industry. The report also provides current and predicted future performance of the pharmaceutical market in different regions of the world. Key countries of each region have been covered and the status of pharmaceutical industry has been provided. Moreover, the report provides information regarding therapeutic segments and key companies. Besides, detail information regarding generics, patented drugs and prescription drugs have been included for all the countries. It provides segment level analysis of the industry along with emerging trends on intellectual property, market opportunities, research collaborations, partnership activities, and guidelines for establishing new ventures. The research will help consultants, industry analysts, and vendors to get in-depth knowledge of the current, past, and future performance of the emerging pharmaceutical markets.

The global pharmaceutical market experienced exponential growth over the past decade but is now witnessing a slump. This slump is attributed to saturation in key markets such as United States and Western Europe, patent expiry of key drug formulations and a static economy. On the other hand, many growing economies in the developing regions of Asia and Latin America are witnessing a continuous high growth rate in the pharmaceutical sector. In the coming years, these markets are expected to continue their robust growth owing to various factors such as increasing prevalence of lifestyle diseases, rise in spending on healthcare and increased access and affordability to healthcare services.This seismic shift in the pharmaceutical markets of the world, away from the major developed powers of the U.S., Japan, France, Germany, Italy, United Kingdom, Spain and Canada to a set of new, dynamic, fast-growing emerging economies of China, Brazil, Russia, India, Mexico, Turkey, and South Korea has created new dynamics. These seven emerging markets of the pharmaceutical sector have been termed as ‘pharmerging markets’. Apart from these E7 economies, many other emerging markets have been recognized as interesting destinations for the major global pharmaceutical players.Unlike the developed world, where health systems provide a more uniform coverage level, the emerging pharmaceutical markets have wide regional health expenditure differences within them. Moreover, recent major developments and global recession have driven disparate rates of evolution in each of these countries. Unlike the pharmaceutical market of United States and Western Europe, the emerging markets are characterized by diverse therapeutic segments, different and complex regulatory law and a fragmented market. The worldwide economic crisis has also added a new layer of complexity to the already challenging environment.

Thus, the need for action and informed direction has never been greater. Apart from the BRIC nations (Brazil, Russia, India and China), positive developments in other parts of the world are also reshaping the pharmaceutical sector. In regions such as Latin America and Asia, Eastern Europe and North Africa, a new set of emerging economies are now rapidly rising. A further 13 nations in these regions have now reached a threshold of economic development and volume of future growth that warrant close and immediate scrutiny. Collectively, the emerging markets undoubtedly offer high potential, with rising GDPs, expanding access to healthcare and an improving IP and regulatory environment in many cases. Nevertheless, these markets are fraught with uncertainty and hurdles. Local companies are strong and entrenched, domestic products well-established, and generics dominate the market in a growing number of countries. Patients invariably bear the highest share of healthcare spend, making issues of willingness and ability to pay key in these low income countries.

Table of Contents

1. OVERVIEW

1.1 STATEMENT OF REPORT

The robust growth in the pharmaceutical markets of emerging world economies has outpaced the overall growth of the global pharmaceutical market. The emerging markets are being driven by rapidly growing economies of these countries, increasing per capita income, increasing prevalence of lifestyle diseases due to rapid urbanization, and low-cost factors. Mainly due to strong performance in the emerging pharmaceutical markets, the global pharmaceutical market is expected to reach US$ 1020 Billion by the end of 2012.

This research study provides extensive and coherent information about pharmaceutical markets in emerging countries. It also gives a detailed statistical and analytical review on the demographics, macroeconomic indicators, disease profile, key drivers and restraints of the emerging pharmaceutical markets. It covers all the key aspects of the various emerging pharmaceutical markets and has broadly outlined the factors that are affecting the industry. The report also provides current and predicted future performance of the pharmaceutical market in different regions of the world. Key countries of each region have been covered and the status of pharmaceutical industry has been provided. Moreover, the report provides information regarding therapeutic segments and key companies. Besides, detail information regarding generics, patented drugs and prescription drugs have been included for all the countries. It provides segment level analysis of the industry along with emerging trends on intellectual property, market opportunities, research collaborations, partnership activities, and guidelines for establishing new ventures.

The research will help consultants, industry analysts, and vendors to get in-depth knowledge of the current, past, and future performance of the emerging pharmaceutical markets.

1.2 SCOPE OF THE REPORT

The principal objectives of this analysis are to:

  • Discuss viable market prospects through the identification of high-growth opportunities in the emerging markets of the pharmaceutical sector.
  • Examine the key dynamics that influence each individual market.
  • Discuss the manufacturing advances, collaborations and major players in important pharmaceutical markets.
  • Obtain an understanding of the regulatory governance and local laws that influences the policies in this sector.
  • Identify the therapeutic segments and important local products for each market.
  • Discuss the important drivers that promote and restrict these emerging pharmaceutical markets with an in-depth analysis of various sectors such as investment, intellectual property regulations including future predictions for growth.

Market figures regarding the current value of the emerging pharmaceutical industry markets are taken from the most recently available data of the global medical products industry.

This report will cover the following categories of the pharmaceutical markets:

  • Demographics and socioeconomic status of each specific market.
  • Major therapeutic segments.
  • Comparison of worldwide trends towards generics with the emerging marketing.
  • Collaborations and partnerships
  • Generics opportunities
  • Regulatory framework and local laws
  • Leading formulations of each specific market.
  • Overview of the intellectual property regulation
  • Research and development
  • Key players in the each emerging market.

This study contains the latest statistics and figures for measuring growth and trends within the marketplace. In addition, a discussion on each market identified as having important role in the future global pharmaceutical market is made. India, China, Russia and markets of the near and far east have been discussed in detail to provide the reader with a deeper understanding of the dynamics of each specific country.

This study's aims are to:

  • Assess the pharmaceutical industry market drivers and bottlenecks, from the perspective of the medical and scientific communities.
  • Discuss the potential benefits of each of the emerging pharmaceutical market for various sectors of the industry.
  • Establish the current total market size and future growth of the various pharmaceutical industry markets of Asia and Latin America and analyze the current size and growth of various segments.
  • Provide current and forecasted market shares by company.
  • Discuss profit/business opportunities by imaging segments.
  • Provide strategic recommendations for near term business opportunities.

1.3 SCOPE OF THE REPORT

The emphasis in this report is on those countries considered to be the emerging pharmaceutical markets of the world, such as India, China, Russia, South Korea, Latin America (Brazil, Mexico, Venezuela, Columbia, Peru, Argentina, Chile), Eastern Europe (Poland, Czech Republic, Romania, Slovenia), Near East (Egypt, Turkey, Saudi Arabia, Israel, Jordan, UAE, Lebanon, and Kuwait). This report analyzes the markets mentioned above. What's more, this examination defines the dollar volume of sales in the U.S. market and analyzes the factors that influence the size and growth of the market segments. The study surveys all companies known to be marketing, manufacturing or developing nutraceutical technologies in the U.S. for the selected segments. Effort has also been made to include sections on smaller companies located around the world.

1.4 METHODOLOGY

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include the non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities like the U.S. Department of Health and Human Services (HHS) and U.S. federal agencies such as the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

1.5 EXECUTIVE SUMMARY

The global pharmaceutical market experienced exponential growth over the past decade but is now witnessing a slump. This slump is attributed to saturation in key markets such as United States and Western Europe, patent expiry of key drug formulations and a static economy. On the other hand, many growing economies in the developing regions of Asia and Latin America are witnessing a continuous high growth rate in the pharmaceutical sector. In the coming years, these markets are expected to continue their robust growth owing to various factors such as increasing prevalence of lifestyle diseases, rise in spending on healthcare and increased access and affordability to healthcare services. This seismic shift in the pharmaceutical markets of the world, away from the major developed powers of the U.S., Japan, France, Germany, Italy, United Kingdom, Spain and Canada to a set of new, dynamic, fast-growing emerging economies of China, Brazil, Russia, India, Mexico, Turkey, and South Korea has created new dynamics. These seven emerging markets of the pharmaceutical sector have been termed as ‘pharmerging markets’.

Back to Top